Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Amortization of Deferred Charges: 2013-2024

Historic Amortization of Deferred Charges for Viridian Therapeutics, Inc.\DE (VRDN) over the last 9 years, with Dec 2024 value amounting to $377,000.

  • Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges rose 41.67% to $102,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $367,000, marking a year-over-year decrease of 16.78%. This contributed to the annual value of $377,000 for FY2024, which is 18.93% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Amortization of Deferred Charges of $377,000 as of FY2024, which was up 18.93% from $317,000 recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges ranged from a high of $377,000 in FY2024 and a low of $87,000 during FY2021.
  • Its 3-year average for Amortization of Deferred Charges is $307,333, with a median of $317,000 in 2023.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges tumbled by 69.04% in 2021 and then surged by 162.07% in 2022.
  • Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges (Yearly) stood at $281,000 in 2020, then slumped by 69.04% to $87,000 in 2021, then soared by 162.07% to $228,000 in 2022, then soared by 39.04% to $317,000 in 2023, then rose by 18.93% to $377,000 in 2024.